Labcorp Holdings Free cash flow decreased by 85.6% to $70.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 165.6%, from -$107.50M to $70.50M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows a downward trend with a -18.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $390.00M | $649.50M | $586.40M | $238.80M | $429.20M | $304.10M | $554.50M | $43.00M | $248.10M | $170.60M | $412.40M | -$163.60M | $432.90M | $161.50M | $665.10M | -$107.50M | $542.70M | $280.50M | $490.30M | $70.50M |
| QoQ Change | — | +66.5% | -9.7% | -59.3% | +79.7% | -29.1% | +82.3% | -92.2% | +477.0% | -31.2% | +141.7% | -139.7% | +364.6% | -62.7% | +311.8% | -116.2% | +604.8% | -48.3% | +74.8% | -85.6% |
| YoY Change | — | — | — | — | +10.1% | -53.2% | -5.4% | -82.0% | -42.2% | -43.9% | -25.6% | -480.5% | +74.5% | -5.3% | +61.3% | +34.3% | +25.4% | +73.7% | -26.3% | +165.6% |